Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9

SLC26A9, a constitutively active Cl(−) transporter, has gained interest over the past years as a relevant disease modifier in several respiratory disorders including Cystic Fibrosis (CF), asthma, and non-CF bronchiectasis. SLC26A9 contributes to epithelial Cl(−) secretion, thus preventing mucus obst...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinto, Madalena C., Quaresma, Margarida C., Silva, Iris A. L., Railean, Violeta, Ramalho, Sofia S., Amaral, Margarida D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658147/
https://www.ncbi.nlm.nih.gov/pubmed/34884866
http://dx.doi.org/10.3390/ijms222313064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658147/
https://www.ncbi.nlm.nih.gov/pubmed/34884866
http://dx.doi.org/10.3390/ijms222313064

Ejemplares similares